medigraphic.com
ISSN 0016-3813 (Impreso)

2005, Número 6

<< Anterior Siguiente >>

Gac Med Mex 2005; 141 (6)


El papel de la leptina en el desarrollo de esteatosis hepática y litiasis biliar

Méndez-Sánchez N, Ponciano-Rodríguez G, Chávez-Tapia NC, Uribe M

Idioma: Español
Referencias bibliográficas: 55
Paginas: 496-500
Archivo PDF: 59.88 Kb.


RESUMEN

La obesidad incrementa el riesgo para varios padecimientos gastro-intestinales como litiasis biliar (LB), esteatosis hepática (EH) y este-atohepatitis no alcohólica. Recientemente observamos una relación entre colesterol HDL, índice de saturación de colesterol en la bilis y leptina en pacientes obesos en reducción de peso. De igual manera la leptina tiene un papel importante en el desarrollo de la EH y probablemente en los mecanismos inflamatorios. El objetivo de este trabajo fue investigar la relación entre la LB y la EH. Se estudiaron a sujetos de la Unidad de Diagnóstico Clínico que acudieron a la realización de una revisión clínica preventiva. Aquellos que presentaron LB o EH por ultrasonido fueron considerados como casos, se compararon con controles sanos. Se tomaron medidas antropométricas, índice de masa corporal (IMC) y concentraciones de leptina, insulina, lípidos séricos, y lipoproteínas por métodos convencionales. Se estudiaron 317 sujetos, quienes fueron divididos en cuatro grupos: LB (n = 100), EH (n = 84), LB + EH (n = 33) y control (n = 100). La edad del grupo control fue significativamente mayor (LB, 52.6 ± 11.6; EH, 49.8 ± 11.1; LB +EH, 51.6 ± 10,5; controles 57.1 ± 7.4), p‹ 0.05. El IMC fue mayor en los grupos de EH (28.7 ± 2.8) y LB +EH (29.0 ± 3.8) que en los grupos de LB (27.4 ± 4.3) y control (27.0 ± 3.0), p‹ 0.05. El grupo de LB (13.7 ± 8.1) presentó las concentraciones más elevadas de leptina comparado con los otros grupos, P ‹ 0.05. Mientras que las concentraciones de insulina fueron similares en los cuatro grupos de sujetos. Los resultados del presente estudio muestran que los sujetos con LB y EH presentan concentraciones elevadas de leptina, comparados con controles. Esto sugiere que la leptina juega un papel importante en la fisiopatología de la LB y EH.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Aguilar-Salinas CA, Vázquez-Chávez C, Gamboa-Marrufo R, García-Soto N, de Jesús Ríos-González J, Holguín R, et al. Obesity, diabetes, hypertension, and tobacco consumption in an urban adult Mexican population. Arch Med Res 2001;32:446-53.

  2. 2. Arroyo P, Loria A, Mendez O. Changes in the household calorie supply during the 1994 economic crisis in Mexico and its implications on the obesity epidemic. Nutr Rev 2004;62:S163-8.

  3. 3. del Río-Navarro BE, Velázquez-Monroy O, Sánchez-Castillo CP, Lara-Esqueda A, Berber A, Fanghanel G, et al. The high prevalence of overweight and obesity in Mexican children. Obes Res 2004;12:215-223.

  4. 4. Villa AR, Escobedo MH, Méndez-Sánchez N. Estimates and trends of obesity prevalence through mortality rates associated of chronic diseases in Mexico. Cac Med Mex 2004;140(Suppl 2):S21-S25.

  5. 5. Sánchez-Castillo CP. Epidemiología de la obesidad, in Obesidad: epidemiología, fisiopatología, y manifestaciones clínicas, Méndez-Sánchez N, Uribe M, Editors, México. Manual Moderno: 2002. p. 5-31.

  6. 6. Mokdad AH, Ford ES, Bowman BA, Dietz WH, Vinicor F, Bales VS, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001 Jama 2003;289:76-79.

  7. 7. Méndez-Sánchez N, Sánchez-Castillo CP, Villar AR, Madrigal H, Merino B, García E, et al. Relación entre sobrepeso y obesidad con mortalidad por cirrosis hepática en México. Rev Gastr Mex 2003;68:176.

  8. 8. Méndez-Sánchez N, Sánchez-Castillo CP, Villa AR, Madrigal H, Merino B, García E, et al. The relationship of overweight and obesity to high mortality rates from liver cirrhosis in Mexico. Ann Hepatol 2004;3:66-71.

  9. 9. Tolman KG, Fonseca V, Tan MH, Dalpiaz A. Narrative review: hepatobiliary disease in type 2 diabetes mellitus. Ann Intern Med 2004;141:946-56.

  10. Bennion LJ, Grundy SM. Effects of obesity and caloric intake on biliary lipid metabolism in mano J Clin Invest 1975; 56: 996-1011.

  11. StahIberg D, Rudling M, Angelin B, Bjorkhem I, Forsell P, Nilsell K, et al. Hepatic cholesterol metabolism in human obesity. Hepatology 1997;25:1447-50.

  12. Lizardi-Cervera J, Motola-Kuba D, Guevara-Gonzalez L. Obesity and its association with cryptogenic cirrhosis and hepatocarcinoma. Gac Med Mex 2004;140(Suppl 2):S77-83.

  13. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.

  14. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.

  15. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002;122:1649-1657.

  16. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndromes. Semin Liver Dis 2001;21:17-26.

  17. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999; 84: 1513-7.

  18. Nakao K, Nakata K, Ohtsubo N, Maeda M, Moriuchi T, Ichikawa T, et al. Association between nonalcoholic fatty liver, markers of obesity, and serum leptin level in young adults. Am J Gastroenterol 2002;97:1796-1801.

  19. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994;372:425-432.

  20. Méndez-Sánchez N, Sánchez-Lara K, Villa AR, Bahena-Aponte J, Chávez Tapia NC, Ramos MH, et al. Adiponectin concentration as protective factor in hepatic steatosis. WorldJ Gas troen terol 2005; in press.

  21. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem 2004;50:1511-1525.

  22. Méndez-Sánchez N, González V, King-Martínez AC, Sánchez H, Uribe M. Plasma leptin and the cholesterol saturation of bile are correlated in obese women after weight loss. J Nutr 2002; 132: 2195-8.

  23. Méndez-Sánchez N, Chávez-Tapia N, Uribe M. Effects of leptin on biliary lipids: potential consequences for gallstone formation and therapy in obesity. Curr Drug Targets Immune Endocr Metabol Disord 2005;5:in press.

  24. Méndez-Sánchez N, Chávez- Tapia NC, Uribe M. [Obesity and non-alcoholic steatohepatitis]. Gac Med Mex 2004;140(Supp12):567-72.

  25. Méndez-Sánchez N, Chávez-Tapia NC, Uribe M. An update on non alcoholic fatty liver disease. Rev Invest Clin 2004; 56: 72-82.

  26. Li Z, Un H, Yang S, Diehl AM. Murine leptin deficiency alters Kupffer cell production of cytokines that regulate the innate immune system. Gastroenterology 2002;123:1304-1310.

  27. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M, et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-50.

  28. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.

  29. Duggirala R, Mitchell BD, Blangero J, Stern MP. Genetic determinants of variation in gallbladder disease in the Mexican-American population. Genet Epidemiol 1999;16:191-204.

  30. Ruhl CE, Everhart JE. Relationship of serum leptin concentration and other measures of adiposity with gallbladder disease. Hepatology 2001;34:877-83.

  31. Ko CW, Beresford SA, Schulte SJ, Matsumoto AM, Lee SP. Incidence, natural history, and risk factors for biliary sludge and stones during pregnancy. Hepatology 2005;41:359-365.

  32. Graewin SJ, Lee K, Tran KQ, Goldblatt MI, Svatek CL, Nakeeb A, et al. Leptin-resistant obese mice do not from biliary crystals on a high cholesterol diet. J Surg Res 2003;114:291.

  33. Graewin SJ, Lee KH, Tran KQ Goldblatt MI, Svatek CL, Nakeeb A, et al. Leptin-resistant obese mice do not form biliary crystals on a high cholesterol diet. J Surg Res 2004;122:145-149.

  34. Graewin SJ, Kiely JM, Lee KH, Svatek CL, Nakeeb A, Pitt HA. Nonobese diabetic mice have diminished gallbladder motility and shortened crystal observation time. J Gastrointest Surg 2004; 8: 824-9; discussion 829-30.

  35. Graewin SJ, Lee KH, Kiely JM, Svatek CL, Nakeeb A, Pitt HA. Gallbladder myocytes are short and cholecystokinin-resistant in obese diabetic mice. Surgery 2004;136:431-436.

  36. Tran KQ Goldblatt MI, Swartz-Basile DA, Svatek C, Nakeeb A, Pitt HA. Diabetes and hyperlipidemia correlate with gallbladder contractility in leptin-related murine obesity. J Gastrointest Surg 2003;7:857-62; discussion 863.

  37. Tran KQ, Graewin SJ, Swartz-Basile DA, Nakeeb A, Svatek CL, Pitt HA. Leptin-resistant obese mice have paradoxically low biliary cholesterol saturation. Surgery 2003; 134: 372-7.

  38. Tran KQ, Swartz-Basile DA, Nakeeb A, Pitt HA. Gallbladder motility in agouti-yellow and leptin-resistant obese mice. J Surg Res 2003; 113: 56-61.

  39. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-6.

  40. Un HZ, Yang SQ, Chuekaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.

  41. Tobe K, Ogura T, Tsukamoto C, Imai A, Matsuura K, Iwasaki Y, et al. Relationship between serum leptin and fatty liver in Japanese male adolescent university students. Am J Gastroenterol 1999;94:3328-35.

  42. Giannini E, Botta F, Cataldi A, Teneoni GL, Ceppa P, Barreea T, et al. Leptin levels in nonalcoholic steatohepatitis and chronie hepatitis C. Hepatogastro-enterology 1999;46:2422-2425.

  43. Uygun A, Kadayifci A, Yesilova Z, Erdil A, Yaman H, Saka M, et al. Serum leptin levels in patients with nonalcoholic steatohepatitis. Am J Gastroenterol 2000;95:3584-3589.

  44. Yang S, Lin H, DiehI AM. Fatty liver vulnerability to endotoxin-induced damage despite NF-kappa B induction and inhibited caspase 3 activation. Am J Physiol Gastrointest Liver Physiol 2001;281:G382-92.

  45. Leclercq lA, Farrell GC, Schriemer R, Robertson GR. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J Hepatol 2002;37:206-13.

  46. Tomita K, Azuma T, Kitamura N, Tamiya G, Ando S, Nagata H, et al. Leptin deficiency enhances sensitivity of rats to alcoholic steatohepatitis through suppression of metallothionein. Am J Physiol Gastrointest Liver Physiol 2004;287:G1078-G1085.

  47. Baffy G, Zhang CY, Glickman JN, Lowell BB. Obesity-related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2. Hepatology 2002;35:753-761.

  48. Angulo P, Alba LM, Petrovic LM, Adams LA, Lindor KD, Jensen MD. Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease. J Hepatol 2004;41:943-949.

  49. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 2004;40:46-54.

  50. Chalasani N, Crabb DW, Cummings OW, Kwo PY, Asghar A, Pandya PK, et al. Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 2003;98:2771-2776.

  51. Petersen KF, Oral EA, Dufour S, Befroy D, Ariyan C, Yu C, et al. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy. J Clin Invest 2002;109:1345-50.

  52. Liangpunsakul S, Chalasani N. Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III). J Clin Gastroenterol 2004;38:891-897.

  53. Gunel N, Coskun U, Toruner FB, Sancak B, Yilmaz E, Cengiz O, et al. Serum leptin levels are associated with tamoxifen-induced hepatic steatosis. Curr Med Res Opin 2003;19:47-50.

  54. Serin E, Ozer B, Gumurdulu Y, Kayaselcuk F, Kul K, Boyacioglu S. Serum leptin level can be a negative marker of hepatocyte damage in nonalcoholic fatty liver. J Gastroenterol 2003;38:471-476.

  55. Chitturi S, Farrell G, Frost L, Kriketos A, Lin R, Fung C, et al. Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology 2002;36:403-409.




2020     |     www.medigraphic.com